| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| A649067-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $100.90 |
| Specifications & Purity | 98% |
|---|---|
| Storage Temp | Desiccated,Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions. In Vitro Alamandine is generated by catalysis of Ang A via ACE2 or directly from Angiotensin 1-7 (Ang-(1-7)). Derived from angiotensin II (Ang II) by Ang II-converting enzyme 2 (ACE2), it shows vasodilating (thus protective) properties. Ang (1-7) can be decarboxylated to a peptide called Alamandine. Alamandine is also an endogenous peptide identified in human blood. Alamandine elevates cAMP concentration in primary endothelial and mesangial cells, also suggesting Gs coupling. Alamandine decreases secretion, expression, and blood levels of leptin. Alamandine induced expression of iNOS and plasminogen activator inhibitor-1 (PAI-1) in adipose tissue and isolated adipocytes. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Alamandine (0.15 μL/h; administered by mini-osmotic pumps; for 6 weeks) treatment ameliorates hypertension and impaires left ventricle (LV) function in SHRs. Also decreases the mass gains of heart and lung in SHRs, suppresses cardiomyocyte cross-sectional area expansion, and inhibits the mRNA levels of atrial natriuretic peptide and brain natriuretic peptide. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male spontaneously hypertensive rats (SHRs, 50-week-old)Dosage: 0.15 μL/h (~50 μg/kg/day) Administration: Administered by mini-osmotic pumps; for 6 weeks Result: Attenuated hypertension, alleviated cardiac hypertrophy, and improved LV function. Form:Solid |
| IUPAC Name | (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid |
|---|---|
| INCHI | InChI=1S/C40H62N12O9/c1-6-22(4)32(37(58)49-29(18-25-19-44-20-46-25)38(59)52-16-8-10-30(52)39(60)61)51-35(56)28(17-24-11-13-26(53)14-12-24)48-36(57)31(21(2)3)50-34(55)27(47-33(54)23(5)41)9-7-15-45-40(42)43/h11-14,19-23,27-32,53H,6-10,15-18,41H2,1-5H3,(H,44,46)(H,47,54)(H,48,57)(H,49,58)(H,50,55)(H,51,56)(H,60,61)(H4,42,43,45)/t22-,23-,27-,28-,29-,30-,31-,32-/m0/s1 |
| InChi Key | QVMYBFKDLPBYSO-GIGALADGSA-N |
| Canonical SMILES | CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)N |
| Isomeric SMILES | CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)N |
| PubChem CID | 44192273 |
| Molecular Weight | 855 |
Enter Lot Number to search for COA:
| Solubility | H2O : 25 mg/mL (29.24 mM; Need ultrasonic) |
|---|
